News

Merck and Dr. Reddy seal biosimilar pact
Enlarge image

BusinessGermany

Merck and Dr. Reddy seal biosimilar pact

07.06.2012 - German Merck Serono and India’s Dr. Reddy’s will co-develop copycat cancer antibody drugs that are losing patent protection.

Darmstadt/Hyberabad – German Merck has made its first step into the emerging biosimilars market while it restructures its business to cope with expected revenue losses for some of its biggest selling pharmaceutical products. On 6 June, Merck KGaA and Dr. Reddy’s Laboratories Ltd. announced plans to co-develop a portfolio of biosimilar monoclonal antibodies (mAbs) in oncology. With the deal, Merck Serono, whose dual Geneva-based headquarters is to be shut down due to restructuring, expands its market presence to emerging markets. Dr. Reddy’s can benefit from Merck’s access to the European and US market and the company’s know-how in antibody development.

According to the terms of the agreement, the companies will share their expertises to bring new cheaper formulations of approved antibodies to the market, which have lost patent protection. The Indian generic drug maker, who markets already four biosimilars in India and other emerging markets, brings in its expertise in making biosimilar versions of originator drugs and will lead early product development including Phase I studies. Merck-Serono, the biotech arm of German Merck KGaA, will contribute its know-how in developing, manufacturing, and commercialising biopharmaceuticals and will take responsibility for manufacturing and late clinical development. Commercially, Merck will hold the rights to market any co-developed in all markets outside the US with the exception of several unspecified emerging markets. In the US, where rules for biosimilar market approval are expected to be established this year, both Merck and Dr Reddy’s will co-market co-developed mAbs and will share profits. Dr Reddy’s will receive royalty payments from Merck. The companies said they will fully share R&D costs.

Just recently, the world’s largest antibody contract manufacturing firm Boehringer Ingelheim announced to step into the biosimilar field. All major pharma players have already established biosimilar pipelines, because the copycat versions of antibody blockbusters such as Herceptin, Mabthera can be developed 30% cheaper than the originators. Experts say, however, that market uptake of biosimilars will depend on acceptance of the copycat drugs in the US.

http://www.european-biotechnology-news.com/news/news/2012-02/merck-and-dr-reddy-seal-biosimilar-pact.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

M&ASwitzerland

09.06.2015 Monsanto plans to acquire Syngenta AG, but seems reluctant to dig deep into its pockets. The Swiss crop chemical maker has now rejected the second offer from the US company.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • SUMMIT (UK)4.03 GBP3.87%
  • KAROLINSKA (S)10.80 SEK3.85%

FLOP

  • THERAMETRICS (CH)0.06 CHF-14.29%
  • SCANCELL HOLDINGS (UK)27.10 GBP-10.41%
  • ALMIRALL (E)16.66 EUR-8.16%

TOP

  • PROTHENA PLC (IE)49.60 USD25.8%
  • DBV Technologies (F)52.00 EUR20.9%
  • BIOINVENT INTERNATIONAL AB (S)2.60 SEK16.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)20.50 SEK-57.1%
  • CELLECTIS (F)30.10 EUR-26.4%
  • NORDIC NANOVECTOR (N)27.00 NOK-22.9%

TOP

  • 4SC (D)4.52 EUR366.0%
  • ADOCIA (F)64.00 EUR352.3%
  • WILEX (D)3.69 EUR334.1%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.75 SEK-70.4%
  • NEOVACS (F)1.11 EUR-69.7%

No liability assumed, Date: 29.06.2015